New agents for the treatment of systemic fungal infections – current status

Bibliography

• WINGARD J: Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. (1994) 19:S49–S53.
   PubMed Web of Science ®Google Scholar
• ANAISSIE E, BODEY GP, KANTARJIAN H et al: New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 11:369–378.
   PubMedGoogle Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: Recent progress and future directions. Clin. Infect. Dis. (1996) 22:S133–S144.
   PubMed Web of Science ®Google Scholar
• KORTING HC, SCHAFER-KORTING M, ZIENICKE H, GEORGII A, OLLERT MW: Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob. Agents Chemother. (1993) 37:2064–8.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, SHEAR NH: Terbinafine: anupdate. j Amer Acad. Dermatol (1997) 37:979–988.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, DE DONCKER P, SCHER RK et al: Itraconazole for the treatment of onychomycosis. bit. j Dermatol (1998) 37:303–308.
   Web of Science ®Google Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B. .1 Liposome Res (1998) 8:443–467.
   Web of Science ®Google Scholar
• TERRELL CL, HUGHES CE: Antifungal agents used for deep-seated mycotic infections. Mayo Clin. Proc. (1992) 67:69–91.
   PubMed Web of Science ®Google Scholar
• GUEHO E, SMITH MT, DE HOOG GS et al.: Contributions to a revision of the genus Trichosporon. Antonie Van Leeuwenhoek (1992) 61:289–316.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, MELCHER GP, RINALDI MG et al.: Trichosporon beige& an emerging pathogen resistant to amphotericin B. 1 Clin. Microbial. (1990) 28:1616–1622.
   Google Scholar
• •An article that emphasises amphotericin B resistance among Trichosporon spp.
   Google Scholar
• SUTTON DA, SANCHE SE, REVANKAR SG, FOTHERGILL AW, RINALDI MG: LI vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.j. Microbial. (1999) 37:2343–2345.
   Web of Science ®Google Scholar
• •An in vitro study demonstrating amphotericin B resistance among A. tetreus isolates.
   Google Scholar
• WALSH M, WHITE L, ATKINSON K, ENNO A: Fungal Pseudallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Auk N Z J. Med.(1992) 22:265–268.
   PubMedGoogle Scholar
• FRANCIS P, WALSH TJ: Approaches to management of fungal infections in cancer patients. Oncology (1992) 6: 133–44.
   Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, NANGIA S, REX JH: Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. I Clin. Microbiol (1999) 37:3946–3951.
   PubMed Web of Science ®Google Scholar
• KARYOTAKIS NC, ANAISSIE EJ, HACHEM R, DIGNANI MC, SAMONIS G: Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J. Infect. Dis. (1993) 168:1311–1313.
   PubMed Web of Science ®Google Scholar
• KARYOTAKIS NC, ANAISSIE EJ: Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob. Agents Chemother. (1994) 38:2660–2662.
   PubMed Web of Science ®Google Scholar
• SABRA R, BRANCH RA: Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob. Agents Chemother. (1991) 35:2509–2514.
   PubMed Web of Science ®Google Scholar
• MEYER RD: Current role of therapy with amphotericin B. Clin. Infect. Dis. (1992) 14\(Suppl. 1):S154–S160.
   PubMed Web of Science ®Google Scholar
• JANKNEGT R, DE MARIE S, BAKKER-WOUDENBERG IA, CROMMELIN DJ: Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clinical Pharmacokinetics (1992) 23:279–291.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, MATTIUZZI GN, MILLER CB et al: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. (1998) 42:606–611.
   PubMed Web of Science ®Google Scholar
• OLDFIELD EC, 3RD, GARST PD, HOSTETTLER C, WHITE M, SAMUELSON D: Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. (1990) 34:1402–1406.
   PubMed Web of Science ®Google Scholar
• STORM G, VAN ETTEN E: Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur. I Clin. Microbiol Infect. Dis. (1997) 16:64–73.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, REX JH: Lipid-based antifungal agents: current status. Curr. Pharm. Design (2001) 7:393–415.
   PubMed Web of Science ®Google Scholar
• ANDRES E, TIPHINE M, LETSCHER-BRU V, HERBRECHT R: Review of new lipid formulations of amphotericin B. Rev Med. Interne (2001) 22:141–150.
   PubMed Web of Science ®Google Scholar
• HANN IM, PRENTICE HG: Lipid-based amphotericin B: a review of the last 10 years of use. Int. Antimicrobial. Agents (2001) 17:161–169.
   PubMed Web of Science ®Google Scholar
• BOYLE JA: Controlled trials of amphotericinB lipid complex. Clin. Infect. Dis. (2000) 31:1117–1118.
   PubMed Web of Science ®Google Scholar
• BJORKHOLM M, RUNARSSON G, CELSING F et al: Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia. Scand. J. Infect. Dis. (2001) 33:316–319.
   PubMed Web of Science ®Google Scholar
• BLAU IW, FAUSER AA: Review of comparative studies between conventional and liposomal amphotericin B (Ambisome (R)) in neutropenic patients with fever of unknown origin and patients with systemic mycosis. Mycoses (2000) 43:325–332.
   PubMed Web of Science ®Google Scholar
• CHOWFIN A, TIGHT R, MITCHELL S: Recurrent blastomycosis of the central nervous system: case report and review. Clin. Infect. Dis. (2000) 30:969–971.
   PubMed Web of Science ®Google Scholar
• JUSTER-REICHER A, LEIBOVITZ E, LINDER N et al: Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection (2000) 28:223–226.
   PubMed Web of Science ®Google Scholar
• WHEAT LJ, CLOUD G, JOHNSON PC et al.: Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob. Agents Chemother. (2001) 45:2354–2357.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, ELLIS RW, JONES SG et al: Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transplant. (2000) 6:588–595.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, REX JH, GALGIANI JN: Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome. Clin. Microbiol (1996) 34:489–495.
   Web of Science ®Google Scholar
• ARIKAN S, AKOVA M, HAYRAN M et al:Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin. Infect. Dis. (1998) 26:903–908.
   PubMed Web of Science ®Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603–618.
   PubMed Web of Science ®Google Scholar
• CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. (2000) 18:2476–2483.
   PubMed Web of Science ®Google Scholar
• FLEMING RV, KANTARJIAN HM, HUSNI R et al: Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma (2001) 40:511–520.
   PubMed Web of Science ®Google Scholar
• WINGARD JR, WHITE MH, ANAISSIE E et al: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. (2000) 31:1155–1163.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, LETSCHER V, ANDRES E, CAVALIER A: Safety and efficacy of amphotericin B colloidal dispersion - an overview. Chemotherapy (1999) 45:67–76.
   PubMed Web of Science ®Google Scholar
• LEENDERS ACAP, DE MARIE S: The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia (1996) 10:1570–1575.
   PubMed Web of Science ®Google Scholar
• PALMER SM, DREW RH, WHITEHOUSE JD et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 72:545–548.
   PubMed Web of Science ®Google Scholar
• RUIJGROK EJ, VULTO AG, VAN ETTEN EWM: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J. Antimicrob. Chemother. (2001) 48:89–95.
   PubMed Web of Science ®Google Scholar
• •An animal study on efficacy of aerosolised amphotericin B formulations.
   Google Scholar
• HIEMENZ JW, LISTER J, ANAISSIE E: Emergency use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical control comparison with amphotericin B. Blood (1995) 86 (Suppl. 1):849a.
   Google Scholar
• JANOFF AS, PERKINS WR, SALETON SL, SWENSON CE: Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B-related toxicities..1 Liposome Res. (1993) 3:451–472.
   Google Scholar
• OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP: Tissue distribution of amphotericin B lipid complex in laboratory animals. J. PharmacoL (1991) 43:831–835.
   Google Scholar
• MATOT I, PIZOV R: Pulmonary extractionand accumulation of lipid formulations of amphotericin B. Grit. Care Med. (2000) 28:2528–2532.
   PubMed Web of Science ®Google Scholar
• ADEDOYIN A, SWENSON CE, BOLCSAK LE et al: A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob. Agents Chemother. (2000) 44:2900–2902.
   PubMed Web of Science ®Google Scholar
• LISTER J: Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. Haematol (1996) 56:18S–23S.
   Google Scholar
• GARNACHO-MONTERO J, ORTIZ-LEYBA C, GARMENDIA JLG, JIMENEZ FJJ: Life-threatening adverse event after amphoterin B lipid complex treatment in a patient treated previously with amphoterin B deoxycholate. Clin. Infect. Dis. (1998) 26:1016.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Efficacy of amphotericin Blipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. (1997) 19:343–347.
   PubMed Web of Science ®Google Scholar
• FIELDING RM, LASIC DD: Novel antifungal drug delivery: stable amphotericin B cholesteryl sulfate discs. Int. J. Pharmaceutics (1991) 75:45–54.
   Web of Science ®Google Scholar
• GUO LSS: Amphotericin B colloidal dispersion: an improved antifungal therapy. Advan. Drug. Delivery Rev (2001) 47:149–163.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, LETSCHER-BRU V, BOWDEN RA et al: Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. j Clin. Microbiol Infect D (2001) 20:460–466.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM BA, HERBRECHT R, KUSNE S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. (1995) 21:1145–1153.
   PubMed Web of Science ®Google Scholar
• WHITE MH, BOWDEN RA, SANDLER E et al.: Amphotericin B colloidal dispersion vs. amphotericin B in the empiric treatment of febrile neutropenic patients. Blood (1996) 88 (Suppl. 1):302a.
   PubMed Web of Science ®Google Scholar
• PATEL R: Amphotericin B colloidal dispersion. Expert Opin. Pharmacother. (2000) 1:475–488.
   PubMedGoogle Scholar
• WORKING PK: Amphotericin B colloidal dispersion - pre-clinical review. Chemotherapy (1999) 45:15–26.
   Google Scholar
• SANDLER ES, MUSTAFA MM, TKACZEWSK I et al: Use of amphotericin B colloidal dispersion in children. .1 Pediat Hematol Oncol. (2000) 22:242–246.
   PubMed Web of Science ®Google Scholar
• WHITE MH, ANAISSIE EJ, KUSNE S et al: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24:635–642.
   PubMed Web of Science ®Google Scholar
• VALERO G, GRAYBILL JR: Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob. Agents Chemother. (1995) 39:2588–2590.
   PubMed Web of Science ®Google Scholar
• WHITE MH, BOWDEN RA, SANDLER ES et al: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27:296–302.
   PubMed Web of Science ®Google Scholar
• TIMMERS GJ, ZWEEGMAN S, SIMOONS-SMIT AM et al: Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. (2000) 25:879–884.
   PubMed Web of Science ®Google Scholar
• JOHNSON JR, KANGAS PJ, WEST M: Serious adverse event after unrecognized substitution of one amphtoericin B lipid preparation for another [letter]. OM Infect. Dis. (1998) 27:1342–1343.
   Web of Science ®Google Scholar
• BISHARA J, WEINBERGER M, LIN AY, PITLIK S: Amphotericin B - not so terrible. Ann. Pharmacother. (2001) 35:308–310.
   PubMed Web of Science ®Google Scholar
• •A case report that emphasises the possibility of a diverse profile of acute infusion-related side effects due to lipid formulations of amphotericin B.
   Google Scholar
• ADLER-MOORE JP, PROFFITT RT: Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin E. Liposome Res. (1993) 3:429–450.
   Google Scholar
• LEE JW, AMANTEA MA, FRANCIS PA et al.: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. (1994) 38:713–718.
   PubMed Web of Science ®Google Scholar
• PROFFITT RT, SATORIUS A, CHIANG SM, SULLIVAN L, ADLER-MOORE JP: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. I Antimicrob. Chemother. (1991) 28 (Suppl. B):49–61.
   Web of Science ®Google Scholar
• BEKERSKY I, FIELDING RM, DRESSLER DE et al: Pharmacokinetics, excretion, and mass balance of C-14 after administration of C-14-cholesterol-labeled AmBisome to healthy volunteers. J. Pharmacol (2001) 41:963–971.
   Google Scholar
• REYES E, CARDONA J, PRIETO A et al: Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells. j Infect. Dis. (2000) 181:2003–2010.
   PubMed Web of Science ®Google Scholar
• GROLL AH, GIRT N, PETRAITIS V et al: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. Infect. Dis. (2000) 182:274–282.
   Web of Science ®Google Scholar
• FRANCIS P, LEE JW, HOFFMAN A et al.:et al.: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection. I Infect. Dis. (1994) 169:356–368.
   Web of Science ®Google Scholar
• ELLIS M, SPENCE D, DE PAUW B et al:An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. OM Infect. Dis. (1998) 27:1406–1412.
   Web of Science ®Google Scholar
• WALSH TJ, GOODMAN JL, PAPPAS P et al.: Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob. Agents Chemother. (2001) 45:3487–3496.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, YELDANDI V, MCEVOY M et al.: Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. (1998) 42:2391–2398.
   PubMed Web of Science ®Google Scholar
• TOLLEMAR J, RINGDEN O, ANDERSSON S et al.: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. (1993) 12:577–582.
   PubMed Web of Science ®Google Scholar
• LAING RBS, MILNE LJR, LEEN CLS, MALCOM GP, STEERS AJ: Anaphylactic reactions to liposomal amphotericin (letter). Lancet (1994) 344:682.
   PubMed Web of Science ®Google Scholar
• TORRE I, LOPEZ-HERCE J, VAZQUEZ P: Anaphylactic reaction to liposomal amphotericin B in children (letter). Ann. Pharmacother. (1996) 30:1037–1038.
   PubMed Web of Science ®Google Scholar
• AYESTARAN A, LOPEZ RM, MONTORO JB et al: Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. (1996) 40:609–612.
   PubMed Web of Science ®Google Scholar
• CAILLOT D, CHAVANET P, CASANOVAS 0 et al.: Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur. Clin. Microbiol. Infect. Dis. (1992) 11:722–725.
   PubMed Web of Science ®Google Scholar
• SORKINE P, NAGAR H, WEINBROUM A et al.: Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. (1996) 24:1311–1315.
   PubMed Web of Science ®Google Scholar
• SCHOFFSKI P, FREUND M, WUNDER R et al.: Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BE Med. J. (1998) 317:379–384.
   PubMed Web of Science ®Google Scholar
• TORRE D, BANFI G, TAMBINI R et al: A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients../. Infection (1998) 37:36–38.
   Web of Science ®Google Scholar
• BARQUIST E, FEIN E, SHADICK D et al: A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. j Trauma (1999) 47:336–340.
   PubMed Web of Science ®Google Scholar
• MOREAU P, MILPIED N, FAYETTE N, RAME JF, HAROUSSEAU JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. I. Antimicrob. Chemother. (1992) 30:535–541.
   PubMed Web of Science ®Google Scholar
• NUCCI M, LOUREIRO M, SILVEIRA F et al.: Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. (1999) 43:1445–1448.
   PubMed Web of Science ®Google Scholar
• ANDERSON RP, CLARK DA: Amphotericin B toxicity reduced by administration in fat emulsion. Ann. Pharmacother. (1995) 29:496–500.
   PubMed Web of Science ®Google Scholar
• GALES MA, GALES BJ, ALFORD KM: Acute renal failure with amphotericin B in lipid emulsion (letter). Ann. Pharmacother.(1996) 30:1036.
   PubMed Web of Science ®Google Scholar
• ERICSSON O, HALLMEN A-C, WIKSTROM I: Amphotericin B is incompatible with lipid emulsions. Ann. Pharmacother. (1996) 30:298.
   PubMed Web of Science ®Google Scholar
• TRISSEL LA: Amphotericin B does not mix with fat emulsion. Amer. J. Health-Syst. Pharm. (1995) 52:1463–1464.
   PubMed Web of Science ®Google Scholar
• WALKERS, TAILOR SAN, LEE M et al: Amphotericin B in lipid emulsions: stability, compatibility, and in vitro antifungal activity. Antimicrob. Agents Chemother. (1998) 42:762–766.
   PubMed Web of Science ®Google Scholar
• OWENS D, FLEMING RA, RESTINO MS, CRUZ JM, HURD DD: Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Amer. J. Health-Syst. Pharm. (1997) 54:683–6.
   PubMed Web of Science ®Google Scholar
• SHADKCHAN Y, SEGAL E: Treatment of experimental candidosis with amphotericin B-intralipid admixtures in immunocompromised mice. J. Antimicrob. Chemother. (2001) 48:245–251.
   PubMed Web of Science ®Google Scholar
• CLEARY JD: Amphotericin B formulated ina lipid emulsion. Ann. Pharmacother. (1996) 30:409–412.
   PubMed Web of Science ®Google Scholar
• ODDS FC, CHEESMAN SL, ABBOTT AB: Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. Antimicrob. Chemother. (1986) 18:473–478.
   Web of Science ®Google Scholar
• LYMAN CA, WALSH TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 44:9–35.
   PubMed Web of Science ®Google Scholar
• SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. Clin. Microbiol Rev (1999) 12:40–79.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-FERNANDEZ JG, CASTANO-SUAREZ E, COMEJO-NAVARRO P et al: Photosensitivity induced by oral itraconazole. Eur. Acad. Dermatol Venereol (2000) 14:501–503.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N Engl. J. Med. (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• KAMI M, SAWADA Y, MORI S et al: Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. Am. J. Hematol (2001) 66:85–
   PubMed Web of Science ®Google Scholar
• BUIJK S, GYSSENS IC, MOUTON JW et al.: Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intens. Care Med. (2001) 27:115–
   PubMed Web of Science ®Google Scholar
• PELZ RK, HENDRIX CW, SWOBODA SM et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. (2001) 233:542–548.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, KONTONYIANNIS DP, HULS C et al.: Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. (1995) 172:599–602.
   PubMed Web of Science ®Google Scholar
• BERRY AJ, RINALDI MG, GRAYBILL JR: Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. (1992) 36:690–692.
   PubMed Web of Science ®Google Scholar
• HAUBRICH RH, HAGHIGHAT D, BOZZETTE SA et al: High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. I Infect. Dis. (1994) 170:238–242.
   PubMed Web of Science ®Google Scholar
• MENICHETTI F, FIORIO M, TOSTI A et al.: High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22:838–840.
   PubMed Web of Science ®Google Scholar
• BALTCH AL, SMITH RP, FRANKE MA et al: Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob. Agents Chemother. (2001) 45:96–104.
   PubMed Web of Science ®Google Scholar
• GALGIANI JN: Coccidioidomycosis. West. Med. (1993) 159:153–171.
   PubMedGoogle Scholar
• WHEAT J, MAWHINNEY S, HAFNER R et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. (1997) 103:223–232.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, BRADSHER RW, KAUFFMAN CA et al.: Treatment of blastomycosis with higher doses of fluconazole. Clin. Infect. Dis. (1997) 25:200–205.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN CA, PAPPAS PG, MCKINSEY DS et al: Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. (1996) 22:46–50.
   PubMed Web of Science ®Google Scholar
• REX JH, PFALLER MA, GALGIANI JN et al: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. (1997) 24:235–247.
   PubMed Web of Science ®Google Scholar
• ••A review article that summarizes the current efficiency of antifungal susceptibility tests in predicting clinical outcome.
   Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al.: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol Infect. Dis. (1999) 33:217–222.
   PubMed Web of Science ®Google Scholar
• REX JH, RINALDI MG, PFALLER MA: Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. (1995) 39:1–8.
   PubMed Web of Science ®Google Scholar
• DENNING DW, HANSON LH, PERLMAN AM, STEVENS DA: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol Infect. Dis. (1992) 15:21–34.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE D, RYCKELYNCK JP: Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. (1993) 24:10–27.
   PubMed Web of Science ®Google Scholar
• HUTTOVA M, HARTMANOVA I, KRALINSKY K et al.: Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. (1998) 17:1012–1015.
   PubMed Web of Science ®Google Scholar
• ABBOTT M, HUGHES DL, PATEL R, KINGHORN GR: Angio-oedema after fluconazole. Lancet (1991) 338:633.
   PubMed Web of Science ®Google Scholar
• AGARWAL A, SAKHAJA V, CHUGH KS: Fluconazole-induced thrombocytopenia. Ann. Intern. Med. (1990) 113:899.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, KAUFFMAN CA, PERFECT J et al: Alopecia associated with fluconazole therapy. Ann. Intern. Med. (1995) 123:354–357.
   PubMed Web of Science ®Google Scholar
• ALBERT SG, DELEON MJ, SILVERBERG AB: Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Grit. Care Med. (2001) 29:668–670.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, UENO K, YOSHIMURA H et al.: Fluconazole-induced convulsions at serum trough concentrations of approximately 80 mu g/mL. Ther. Drug Monk (2000) 22:635–636.
   PubMed Web of Science ®Google Scholar
• JORDAN MK, POLIS MA, KELLY G et al: Effects of fluconazole and clarithromycin on rifabutin and 25-0- desacetylrifabutin pharmacokinetics. Antimicrob. Agents Chemother. (2000) 44:2170–2.
   PubMed Web of Science ®Google Scholar
• TUCKER RIVI, DENNING DW, HANSON LH et al.: Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin. Infect. Dis. (1992) 14:165–74.
   PubMed Web of Science ®Google Scholar
• ROBINSON RE NAHATA MC, OLSHEFSKI RS: Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann. Pharmacother. (2000) 34:1406–1409.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS J, MICHAUX J-L, BOSLY A et al: Pharmacokinetics and safety of seven days of intravenous (IV) itraconazole followed by two weeks oral itraconazole solution in patients with haematological malignancy. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (1996).
   Google Scholar
• VANDEWOUDE K, VOGELAERS D, DECRUYENAERE J et al: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. (1997) 41:2714–2718.
   PubMed Web of Science ®Google Scholar
• ZHOU HH, GOLDMAN M, WU J et al: A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol (1998) 38:593–602.
   PubMed Web of Science ®Google Scholar
• DE BEULE K, VAN GESTEL J: Pharmacology of itraconazole. Drugs (2001) 61:27–37.
   PubMed Web of Science ®Google Scholar
• WILLEMS L, VAN DER GEEST R, DE BEULE K: Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. Clin. Pharm. Ther. (2001) 26:159–169.
   Web of Science ®Google Scholar
• •A review article summarising the formulations of itraconazole that have become available more recently.
   Google Scholar
• BAILEY EM, KRAKOVSKY DJ, RYBAK MJ: The triazole antifungal agents: A review of itraconazole and fluconazole. Pharmacotherapy (1990) 10:146–153.
   PubMed Web of Science ®Google Scholar
• UZUN O, ARIKAN S, KOCAGOZ S, SANCAK B, UNAL S: Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn. Microbiol Infect. Dis. (2000) 38:101–107.
   PubMed Web of Science ®Google Scholar
• AL-MOHSEN IZ, SUTTON DA, SIGLER L et al: Acrophialophora fusispora brain abscess in a child with acute lymphoblastic leukemia: Review of cases and taxonomy. J. Microbiol. (2000) 38:4569–4576.
   Web of Science ®Google Scholar
• BADDLEY JW, MOSER SA, SUTTON DA, PAPPAS PG: Microascus cinereus (anamorph Scopulariopsis) brain abscess in a bone marrow transplant recipient. Clin. Microbiol (2000) 38:395–397.
   Web of Science ®Google Scholar
• BONIFAZ A, CARRASCO-GERARD E, SAUL A: Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses (2001) 44:1–7.
   PubMed Web of Science ®Google Scholar
• CAILLOT D, BASSARIS H, MCGEER A et al: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. (2001) 33:E83–E90.
   PubMed Web of Science ®Google Scholar
• CORONEL B, LEVRON JC, DOREZ D et al: Itraconazole lung concentrations in haematological patients. Mycoses (2000) 43:125–127.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS M, MAERTENS J, VAN HOOF A et al.: Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. I Antimicrob. Chemother. (2001) 48:97–103.
   Web of Science ®Google Scholar
• BOOGAERTS M, WINSTON DJ, BOW EJ et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy - a randomized, controlled trial. Ann. Intern. Med. (2001) 135:412–422.
   PubMed Web of Science ®Google Scholar
• ANDES D, PROCTOR R, BUSH RK, PASIC TR: Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis. Clin. Infect. Dis. (2000) 31:202–4.
   PubMed Web of Science ®Google Scholar
• STEVENS DA, SCHWARTZ HJ, LEE JY et al.: A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl. Med. (2000) 342:756–762.
   PubMed Web of Science ®Google Scholar
• NGUYEN MH, YU CY: Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. Antimicrob. Chemother. (1998) 42:253–256.
   Web of Science ®Google Scholar
• BRADDLEY JW, SMITH AM, MOSER SA, PAPPAS PG: Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University Hospital. Diagn. Microbiol Infect. Dis. (2001) 39:199–201.
   PubMed Web of Science ®Google Scholar
• MULLER FMC, WEIG M, PETER J, WALSH TJ: Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. j Antimicrob. Chemother. (2000) 46:338–341.
   Google Scholar
• GOLDMAN M, CLOUD GA, SMEDEMA M et al: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob. Agents Chemother. (2000) 44:1585–1587.
   Google Scholar
• DANNAOUI E, BOREL E, MONIER MF et al.: Acquired itraconazole resistance in Aspergillus fumigatus. I Antimicrob. Chemother. (2001) 47:333–340.
   PubMed Web of Science ®Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA et al.: hi vitro activity of voriconazole against selected fungi. Med. Mycol. (1998) 36:239–242.
   PubMed Web of Science ®Google Scholar
• MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1999) 28:250–255.
   PubMed Web of Science ®Google Scholar
• MICHALLET M, PERSAT F, KRANZHOFER N et al: Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant. (1998) 21:1239–1243.
   PubMed Web of Science ®Google Scholar
• MEUNIER F: Future directions of antimycotic therapy. Mycoses (1994) 37:77–82.
   PubMed Web of Science ®Google Scholar
• DENNING DW, TUCKER RM, HANSON LH, STEVENS DA: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. (1989) 86:791–800.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS MA, MAERTENS J, VAN DER GEEST R et al: Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother. (2001) 45:981–985.
   PubMed Web of Science ®Google Scholar
• LEBRUN-VIGNES B, ARCHER VC, DIQUET B et al: Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. BE I Clin. Pharmacol. (2001) 51:443–450.
   PubMed Web of Science ®Google Scholar
• WAKASUGI H, ISHIZUKA R, KOREEDA N et al.: Effect of itraconazole on digoxin clearance in patients with congestive heart failure." Pharm. Soc. J. (2000) 120:807–811.
   PubMed Web of Science ®Google Scholar
• REX JH: Itraconazole-digoxin interaction. Ann. Intern. Med. (1992) 116:526.
   Web of Science ®Google Scholar
• SCHOLER HJ: Flucytosine. In: AntifungalChemotherapy Speller DCE (Ed.), Wiley & Sons, Chichester, UK (1980): 35–106.
   Google Scholar
• BENNETT JE, DISMUKES WE, DUMA RJ et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl. J. Med. (1979) 301:126–131.
   PubMed Web of Science ®Google Scholar
• VERMES A, VAN DER SIJS H, GUCHELAAR HJ: Flucytosine: Correlation between toxicity and pharmacokinetic parameters. Chemotherapy (2000) 46:86–94.
   PubMed Web of Science ®Google Scholar
• CUENCA-ESTRELLA M, DIAZ-GUERRA TM, MELLADO E, RODRIGUEZ-TUDELA JL: Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. Clin. Microbial. Infect. Dis. (2001) 20:276–279.
   Web of Science ®Google Scholar
• WHELAN WL: The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Critical Reviews in Microbiology (1987) 15: 45–56.
   Google Scholar
• MAYANJA-KIZZA H, OISHI K, MITARAI S et al.: Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. (1998) 26:1362–1366.
   PubMed Web of Science ®Google Scholar
• DIAMOND DM, BAUER M, DANIEL BE et al.: Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob. Agents Chemother. (1998) 42:528–533.
   PubMed Web of Science ®Google Scholar
• VERMES A, GUCHELAAR HJ, DANKERT J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions." Antimicrob. Chemother. (2000) 46:171–179.
   PubMed Web of Science ®Google Scholar
• YOON SA, VAZQUEZ JA, STEFFAN PE, SOBEL JD, AKINS RA: High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother. (1999) 43:836–845.
   PubMed Web of Science ®Google Scholar
• •Amphotericin B reistance in Candida lusitaniae isolates.
   Google Scholar
• BOKEN DJ, SWINDELLS S, RINALDI MG: Fluconazole-resistant Candida albicans. Clin. Infect. Dis. (1993) 17:1018–1021.
   PubMed Web of Science ®Google Scholar
• REX JH, LOZANO-CHIU M, PAETZNICK V et al: Susceptibility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) collaborative study #34: Isolates of C. krusei are often resistant to both fluconazole and amphotericin B. 36th Annual Meeting of the Infectious Diseases Society of America. Denver,CO (1998) Abstract 324.
   Google Scholar
• •An in vitro investigation demonstrating amphotericin B resistance in C. kruseL
   Google Scholar
• STEVENS DA, KULLBERG BJ, BRUMMER E et al: Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. (2000) 38:305–315.
   PubMed Web of Science ®Google Scholar
• DENNING DW: Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J. Antimicrob. Chemother. (1997) 40:611–614.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH: Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbial. (1998) 1:547–557.
   PubMed Web of Science ®Google Scholar
• DENNING DW: Treatment of invasive aspergillosis. " Infect. (1994) 28 (Suppl. 1):25–33.
   Web of Science ®Google Scholar
• DENNING DW: Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. (1994) 7:456–462.
   Web of Science ®Google Scholar
• PATEL R, PORTELA D, BADLEY AD et al.: Risk factors of invasive Candida and non- Candida fungal infections after liver transplantation. Transplantation (1996) 62:926–934.
   PubMed Web of Science ®Google Scholar
• BODEY GP: Infection in cancer patients: a continuing association. Am. Med. (1986) 81:11–26.
   PubMed Web of Science ®Google Scholar
• MEADE RH: Drug therapy reviews: clinical pharmacology and therapeutic use of antimycotic drugs. Am. I Hosp. Pharm. (1979) 36:1326–1334.
   PubMedGoogle Scholar
• MEHTA RT, HOPFER RL, GUNNER LA, JULIANO RL, LOPEZ-BERESTEIN G: Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. (1987) 31:1897–1900.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, REX JH: NYSTATIN LE Current Opinion in Investigational Drugs (2001) 2:488–495.
   PubMedGoogle Scholar
• •A detailed review on liposomal nystatin.
   Google Scholar
• JESSUP CJ, WALLACE TJ, GHANNOUM MA: Evaluation of antifungal activity of Nyotran against various pathogenic fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997) Abstract F–88.
   Google Scholar
• WALLACE TL, PAETZNICK V, COSSUM PA et al.: Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. (1997) 41:2238–2243.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V et al.: In vitro activity of liposomal nystatin compared with amphotericin B and fluconazole against clinical Candida isolates. 98th General Meeting of the American Socien, for Microbiology Atlanta, GA (1998) Abstract C–280.
   Google Scholar
• CARILLO-MUNOZ AJ, QUINDOS G, TUR C et al.: In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulfate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole, and itraconazole. Antimicrob. Chemother. (1999) 44:397–401.
   Web of Science ®Google Scholar
• MEHTA RT, HAYMAN A, SARIN P, LOPEZ-BERESTEIN G: AR-121. Drugs Future (1994) 19:724–730.
   Google Scholar
• MEHTA RT, HOPFER RL, MCQUEEN T, JULIANO RL, LOPEZ-BERESTEIN G: Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. (1987) 31:1901–1903.
   PubMed Web of Science ®Google Scholar
• DENNING DW, WARN P: Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. (1999) 43:2592–2599.
   PubMed Web of Science ®Google Scholar
• ROLSTON K, BAIRD I, GRAHAM DR, JAUREGUI L: Treatment of refractory episodes of candidemia in non-neutropenic patients with liposomal nystatin (Nyotran). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract LB–1.
   Google Scholar
• GROLL AH, GONZALEZ CE, GIRT N et al.: Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non- compartmental pharmacokinetics. I Antimicrob. Chemother. (1999) 43:95–103.
   Web of Science ®Google Scholar
• GROLL AH, PETRAITIS V, PETRAITIENE R et al.: Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1999) 43:2463–2467.
   PubMed Web of Science ®Google Scholar
• GROLL AH, MICKIENE D, WERNER K et al: Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob. Agents Chemother. (2000) 44:950–957.
   PubMed Web of Science ®Google Scholar
• RIOS A, ROSENBLUM M, CROFOOT G et al.: Pharmacokinetics of nystatin LF in patients with HIV infection. J. Infect. Dis. (1993) 168:253–254.
   PubMed Web of Science ®Google Scholar
• WILLIAMS AH: Multicenter study to evaluate the safety and efficacy of varioius doses of liposome-encapsulated Nystatin in nonneutropenic patients with candidemia. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) Abstract J–1420.
   Google Scholar
• OFFNER FCJ, HERBRECHT R, ENGELHARD D et al: EORTC-IFCT Phase II study on liposomal nystatin in patients with invasive aspergillosis infections, refractory to or intolerant of conventional / lipid amphotericin B. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1102.
   Google Scholar
• •A clinical study that demonstrates the efficacy of liposomal nystatin as a salvage agent in aspergillosis.
   Google Scholar
• POWLES R, MAWHORTER S, WILLIAMS T: Liposomal nystatin (Nyotran) vs. amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) Abstract LB–4.
   Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al: Open, randomised comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL (2001) Abstract J–688.
   Google Scholar
• ••A clinical study that demonstrates theefficacy of voriconazole in primary therapy of aspergillosis.
   Google Scholar
• RESTREPO MI, NAJVAR LK, BARCHIESI F, LUTHER ME GRAYBILL JR: Treatment of murine cryptococcal meningitis with UR-9751 and UR- 9746. Med. Mycol. (2000) 38:221–224.
   PubMed Web of Science ®Google Scholar
• KHAN JK, MONTASERI H, POGLOD M et al.: Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. Antimicrob. Agents Chemother. (2000) 44:910–915.
   PubMed Web of Science ®Google Scholar
• JOHNSON EM, SZEKELY A, WARNOCK DW: In vitro activity of SYN-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob. Agents Chemother. (1999) 43:1260–1263.
   PubMed Web of Science ®Google Scholar
• SALAMA SM, ATWAL H, GANDHI A et al.: In vitro and in vivo activities of 5YN2836, 5YN2869, 5YN2903, and 5YN2921: new series of triazole antifungal agents. Antimicrob. Agents Chemother. (2001) 45:2420–2426.
   PubMed Web of Science ®Google Scholar
• KURTZ MB, REX JH: Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. (2001) 56:463–475.
   Google Scholar
• ••A detailed review article on echinocandins.
   Google Scholar
• GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on beta- 1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269–280.
   PubMed Web of Science ®Google Scholar
• HALL GS, MYLES C, PRATT KJ, WASHINGTON JA: Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. (1988) 32:1331–1335.
   Google Scholar
• KURTZ MB, HEATH IB, MARRINAN J et al.: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-13-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480–1489.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK et al: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45:1854–1859.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45:327–330.
   PubMed Web of Science ®Google Scholar
• DOUGLAS CM, BOWMAN JC, ABRUZZO GK et al: The glucan synthesis inhibitor caspofungin acetate (Cancidas, MK-0991, L-743872) kills Aspergillus fumigatus hyphal tips in vitro and is efficacious against disseminated aspergillosis in cyclophosphamide-induced chronically leukopenic mice. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1683.
   Google Scholar
• •An in vitro study that demonstrates the combined fungistatic and fungicidal activity of caspofungin against Aspergillus.
   Google Scholar
• GOLDBERG J, CONNOLLY P, SCHNIZLEIN-BICK C et al: Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob. Agents Chemother. (2000) 44:1624–1629.
   PubMed Web of Science ®Google Scholar
• HECTOR RE ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob. Agents Chemother. (1990) 34:587–593.
   PubMed Web of Science ®Google Scholar
• CHIOU CC, MAVROGIORGOS N, TILLEM E, HECTOR R, WALSH TJ: Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2001) 45:3310–3321.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob. Agents Chemother. (2000) 44:2547–2548.
   PubMed Web of Science ®Google Scholar
• LI RK, RINALDI MG: In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother. (1999) 43:1401–1405.
   PubMed Web of Science ®Google Scholar
• DE LUCCA AJ, WALSH TJ: Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob. Agents Chemother. (1999) 43:1–11.
   PubMed Web of Science ®Google Scholar
• MEULBROEK JA, OLEKSIJEW A, TOVCIMAK A et al.: Efficacy of A-175800.0, an inhibitor of fungal cell wall synthesis, against experimental systemic candidiasis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract F–82.
   Google Scholar
• NILIUS AM, RANEY PM, HENSEY-RUDLOFF DM et al.: In vitro activity of A-192411.29, a novel antifungal lipopeptide. Antimicrob. Agents Chemother. (2000) 44:1242–1246.
   PubMed Web of Science ®Google Scholar
• IWAMOTO T, FUJIE A, SAKAMOTO K et al.: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. Antibiot. (Tokyo) (1994) 47:1084–1091.
   PubMed Web of Science ®Google Scholar
• IWAMOTO T, FUJIE A, NITTA K et al: WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. Antibiot. (Tokyo) (1994) 47:1092–7.
   PubMed Web of Science ®Google Scholar
• HELMERHORST EJ, REIJNDERS IM, T HOF WM et al: Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. (1999) 43:702–704.
   PubMed Web of Science ®Google Scholar
• HAWSER S, BORGONOVI M, MARKUS A, ISERT D: Mulundocandin, an echinocandin-like lipopeptide antifungal agent: Biological activities in vitro. Antibiot. (1999) 52:305–310.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ JM, KELLY VA, KINSMAN OS et al: Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. (1998) 42:2274–2278.
   PubMed Web of Science ®Google Scholar
• ODDS FC: Sordarin antifungal agents. Expert Opin. Ther. Patents (2001) 11:283–294.
   Web of Science ®Google Scholar
• DOMINGUEZ JM, GOMEZ-LORENZO MG, MARTIN JJ: Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid. J. Biol. Chem. (1999) 274:22423–22427.
   PubMed Web of Science ®Google Scholar
• HERREROS E, MARTINEZ CM, ALMELA MJ et al: Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. (1998) 42:2863–2869.
   PubMed Web of Science ®Google Scholar
• HERREROS E, ALMELA MJ, LOZANO S, DE LAS HERAS FG, GARGALLO-VIOLA D: Antifungal activities and cytotoxicity studies of six new azasordarins. Antimicrob. Agents Chemother. (2001) 45:3132–3139.
   PubMed Web of Science ®Google Scholar
• AVILES P, FALCOZ C, SAN ROMAN R, GARGALLO-VIOLA D: Pharmacokinetics-pharmaco dynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis. Antimicrob. Agents Chemother. (2000) 44:2333–2340.
   PubMed Web of Science ®Google Scholar
• AVILES P, PATEMAN A, ROMAN RS et al.: Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration. Antimicrob. Agents Chemother. (2001) 45:2787–2792.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, AVILES P, JIMENEZ E, CABALLERO J, GARGALLO-VIOLA D: Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob. Agents Chemother. (2000) 44:3389–3394.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Screening of sordaricin derivatives against endemic fungal pathogens. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract F–58.
   Google Scholar
• AVILES P, ALIOUAT EM, MARTINEZ A et al.: In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats. Antimicrob. Agents Chemother. (2000)44:1284–1290.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-SOUSA A, ALVAREZ MEA, PARRA C, BAQUERO F: Activity on clinical yeast isolates of a new antifungal agent, GM237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract F–56.
   Google Scholar
• CUENCA-ESTRELLA M, MELLADO E, DIAZ-GUERRA TM, MONZON A, RODRIGUEZ-TUDELA JL: AZASORDARINS: Susceptibility of fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida spp. to GW 471558. Antimicrob. Agents Chemother. (2001) 45:1905–1907.
   PubMed Web of Science ®Google Scholar
• ALVAREZ ME, HERREROS E, SANCHEZ-SOUSA A, D G-V, BAQUERO F: hi vitro activity of sordarins in combination with other systemic antifungal agents against Candida albicans, Aspergillus spp., and Scedasporium apiaspermum. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract J–12.
   Google Scholar
• CAPA L, MEND OZA A, LAVANDERA JL, GOMEZ DE LAS HERAS F, GARCIA-BUSTOS JF: Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Chemother. (1998) 42:2694–2699.
   PubMed Web of Science ®Google Scholar
• AVILES P, FALCOZ C, GUILLEN MJ et al: Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding. Antimicrob. Agents Chemother. (2001) 45:2746–2754.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. Antimicrob. Agents Chemother. (2000) 44:1874–1877.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR L, FOTHERGILL A, BOCANEGRA R, DE LAS HERAS FG: Activities of sordarins in murine histoplasmosis. Antimicrob. Agents Chemother. (1999) 43:1716–1718.
   PubMed Web of Science ®Google Scholar
• GATEHOUSE DG, WILLIAMS TC, SULLIVAN AT et al.: Sordarins: Toxiocological evaluation and safety pharmacology in rats and dogs. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract J–75.
   Google Scholar
• ESPINEL-INGROFF A: In vitro activities of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. ./. Clin. Microbiol (1998) 36:198–202.
   Web of Science ®Google Scholar
• CLANCY CJ, NGUYEN MH: LI vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. j Clin. Microbiol Infect. Dis. (1998) 17:573–575.
   PubMed Web of Science ®Google Scholar
• CARRILLO AJ, GUARRO J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. (2001) 45:2151–2153.
   PubMed Web of Science ®Google Scholar
• LI RK, CIBLAK MA, NORDOFF N et al.: LI vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum. Antimicrob. Agents Chemother. (2000) 44:1734–1736.
   Google Scholar
• NUCCI M, AKITI T, BARREIROS G et al: Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection.j Clin. Microbiol. (2001) 39:514–518.
   Google Scholar
• YILDIRAN ST, SARACLI MA, FOTHERGILL AW, RINALDI MG: In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including posaconazole and voriconazole. Eur. Microbiol Infect. D. (2000) 19:317–319.
   PubMed Web of Science ®Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ, REX JH: Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J. Clin. Microbiol (1999) 37:2755–2759.
   PubMed Web of Science ®Google Scholar
• QUINDOS G, CARRILLO-MUNOZ AJ, AREVALO MP et al: In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy (2000) 46:395–401.
   PubMed Web of Science ®Google Scholar
• RYDER NS, LEITNER I: Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. (2001) 39:91–95.
   PubMed Web of Science ®Google Scholar
• WEIG M, MULLER FMC: Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. (2001) 45:966–968.
   PubMed Web of Science ®Google Scholar
• WILDFEUER A, SEIDL HP, PAULE I, HABERREITER A: LI vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41:309–319.
   PubMed Web of Science ®Google Scholar
• JOHNSON EM, SZEKELY A, WARNOCK DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. j Antimicrob. Chemother. (1998) 42:741–745.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: LI vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J.Microbiol. (2001) 39:954–958.
   Web of Science ®Google Scholar
• TROKE PF, BRAMMER KW, HITCHCOCK CA, YONREN S, SARANTIS N: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis. 35th Llterscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1995) Abstract F–73.
   Google Scholar
• LAW D, MOORE CB, DENNING DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41:2310–2311.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, ARZENI D, FOTHERGILL AW et al.: LI vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob. Agents Chemother. (2000) 44:226–229.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2001) 45:2862–2864.
   Google Scholar
• GALGIANI JN, LEWIS ML: LI vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. (1997) 41:180–183.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: LI vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillusspp. Antimicrob. Agents Chemother. (1997) 41:1124–1126.
   Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: LI vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia (1998) 141:73–77.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole Posaconazole and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. ./. Clin. Microbiol (1998) 36:2950–2956.
   Web of Science ®Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: An in vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi. 36th Llterscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA (1996) p. 115, Abstract F–89.
   Google Scholar
• MANAVATHU EK, CUTRIGHT JL, LOEBENBERG D, CHANDRASEKAR PH: A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillusspp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. (2000) 46:229–234.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, SCHIMIZZI AM, NAJVAR LK et al: Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2001) 45:1355–1359.
   PubMed Web of Science ®Google Scholar
• SANCHE SE, FOTHERGILL AW, RINALDI MG: Interspecies variation of the suceptibility of Fusarium species to Schering 56592 in vitro. 37th Llterscience Conference on Antimicrobial Agents and Chemotherapy (1997)
   Google Scholar
• UCHIDA K, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrobial Agents (2001) 18:167–172.
   PubMed Web of Science ®Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL et al: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43:589–591.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER S, JONES RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (1997) 41:233–235.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al: In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. (1998) 42:3242–3244.
   PubMed Web of Science ®Google Scholar
• MUNAYYER H, SHAW KJ, HARE RS et al.: SCH 56592 is a potent inhibitor of sterol C14 demethylation in fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA (1996) p. 115, Abstract F–92.
   Google Scholar
• FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: LI vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42:313–318.
   PubMed Web of Science ®Google Scholar
• MOORE CB, WALLS CM, DENNING DW: In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. (2000) 44:441–443.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, DIEKEMA DJ, JONES RN et al.: International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. Chi]. Microbial. (2001) 39:3254–3259.
   Web of Science ®Google Scholar
• YAMAZUMI T, PFALLER MA, MESSER SA et al: LI vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoforman.s Antimicrob. Agents Chemother. (2000) 44:2883–2886.
   Google Scholar
• HATA K, KIMURA J, MIKI H et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237–2242.
   PubMed Web of Science ®Google Scholar
• HATA K, UNEO J, MIKI H et al: ER-30346, a novel antifungal triazole: III. LI vitro activity and its mode of action. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1995) Abstract 92:129.
   Google Scholar
• PATTERSON BE, COATES PE: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1995) Abstract F–78.
   Google Scholar
• PATTERSON BE, ROFFEY S, JEZEQUEL SG, JONES B: UK-109,496, a novel, wide spectrum tirazole derivative for the treatment of fungal infections: Disposition in marl. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1995) Abstract F–79.
   Google Scholar
• ALLY R, SCHURMANN D, KREISEL W et al.: A randomized, double-blind, double- dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Chi]. Infect. Dis. (2001) 33:1447–1454.
   PubMed Web of Science ®Google Scholar
• HWANG YKW, J00 NH, TEE GY et al: Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. Haematologia (2001) 31:73–80.
   PubMedGoogle Scholar
• SCHWARTZ S, MILATOVIC D, THIEL E: Succesful treatment of cerebral aspergillosis with novel triazole (voriconazole) in a patient with acute leukemia. BE J. Haematol (1997) 97:663–665.
   PubMed Web of Science ®Google Scholar
• SCHLAMM HT, COREY L, BROWN J, PERFECT JR: Voriconazole for salvage treatment of invasive aspergillosis. Chi]. Infect. Dis. (2000) 31:265.
   Google Scholar
• REIS A, SUNDMACHER R, TINTELNOT K et al.: Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. BL J. Ophthalmol (2000) 84:932–933.
   Web of Science ®Google Scholar
• JABADO N, CASANOVA JL, HADDAD E et al: Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. (1998) 27:1437–1441.
   PubMed Web of Science ®Google Scholar
• MUNOZ P, MARIN M, TORNERO P et al.: Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. (2000) 31:1499–1501.
   PubMed Web of Science ®Google Scholar
• NESKY MA, MCDOUGAL EC, PEACOCK JE, JR: Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Chi]. Infect. Dis. (2000) 31:673–677.
   PubMed Web of Science ®Google Scholar
• POZA G, MONTOYA J, REDONDO C et al: Meningitis caused by Pseudallescheria boydii treated with voriconazole. Chi]. Infect. Dis. (2000) 30:981–982.
   PubMed Web of Science ®Google Scholar
• HEITMANN L, COMETTA A, HURNI M et al.: Right-sided pacemaker-related endocarditis due to Acremonium species. Clin. Infect. Dis. (1997) 25:158–160.
   PubMed Web of Science ®Google Scholar
• RADWANSKI E, KOSOGLOU T, LI M: Bioavailability of an oral suspension relative to a solid dosage form in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract A–86.
   Google Scholar
• NOMEIR AA, KUMARI P, HILBERT MJ et al: Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. (2000) 44:727–731.
   PubMed Web of Science ®Google Scholar
• HACHEM RY, RAAD II, AFIF CM et al.: An open, noncomparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. 40th Llterscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000)
   Google Scholar
• NIETO L, NORTHLAND R, PITTISUTTITHUM P et al: Posaconazole equivalent to fluconazole in the treatment of oropharyngeal candidiasis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1108.
   Google Scholar
• VAZQUEZ JA, NORTHLAND R, MILLER S, DICKINSON G, WRIGHT G: Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1107.
   Google Scholar
• CACCIAPUOTI A, LOEBENBERG D, CORCORAN E et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. (2000) 44:2017–2022.
   Google Scholar
• KIRKPATRICK WR, MCATEE RK, FOTHERGILL AW et al.: Efficacy of posaconazole in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44:780–782.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. (2001) 45:857–869.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT LJ, SCHNIZLEIN-BICK C et al: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob. Agents Chemother. (2000) 44:2604–2608.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, SAKAI R, SONODA J et al: ER-30346, a novel antifungal triazole: IV. Pharmacokinetics and toxicological studies in mice, rats, and dogs. 35th Llterscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1995) Abstract F–94.
   Google Scholar
• HATA K, KIMURA J, MIKI H et al: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. (1996) 40:2243–2247.
   PubMed Web of Science ®Google Scholar
• MIKAMO H, YIN XH, HAYASAKI Y, SATOH M, TAMAYA T: Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Chemotherapy (2001) 47:377–380.
   PubMed Web of Science ®Google Scholar
• ROBERTS J, SCHOCK K, MARINO S, ANDRIOLE VT: Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44:3381–3388.
   PubMed Web of Science ®Google Scholar
• BEALE M, QUEIROZ-TELLES F, BANHEGYI D, LI N, PIERCE PF: Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. 41st Llterscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL (2001) Abstract J–1621.
   Google Scholar
• HOSSAIN MA, GHANNOUM MA: New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Investig. Drugs (2000) 9:1797–1813.
   PubMed Web of Science ®Google Scholar
• KAPPE R: Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses (1999) 42:83–86.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN M, PAI S, MENON S et al.: SCH 56592: Rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract A–87.
   Google Scholar
• UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: LI vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156–1157.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, COFFMAN S: LI vitro susceptibilities of clinical yeast isolates to a new echinocandin derivatives, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41:763–766.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol Infect. Dis. (1998) 30:251–255.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: LI vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergr://usspp. Antimicrob. Agents Chemother. (1998) 42:2726–2730.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1612–1614.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol Infect. Dis. (1998) 32:33–37.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326–2332.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusariumspp. Antimicrob. Agents Chemother. (2002) 46:245–247.
   PubMed Web of Science ®Google Scholar
• CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2000) 44:3302–3305.
   PubMed Web of Science ®Google Scholar
• CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol Infect. Dis. (2001) 39:99–103.
   PubMed Web of Science ®Google Scholar
• FRANZOT SP, CASADEVALL A: Pneumoncandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41:331–336.
   PubMed Web of Science ®Google Scholar
• FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. Infect. Dis. (2000) 182:1791–1795.
   Web of Science ®Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi. 36th Llterscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA (1996) Abstract F–29.
   Google Scholar
• DEL POETA M, CRUZ MC, CARDENAS ME, PERFECT JR, HEITMAN J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-099 1/caspofungin acetate (L- 743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44:739–746.
   PubMed Web of Science ®Google Scholar
• DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41:1835–1836.
   PubMed Web of Science ®Google Scholar
• MAKI K, MORISHITA Y, IGUCHI Y et al.: LI vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract F–141.
   Google Scholar
• MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. Antimicrob. Chemother. (2000) 46:485–487.
   Web of Science ®Google Scholar
• TAWARA S, IKEDA F, MAKI K et al: LI vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. (2000) 44:57–62.
   PubMed Web of Science ®Google Scholar
• NAKAI T, UNO J, MIYAJI M: LI vitro activity of FK463, a novel antifungal lipopeptide, against clinically important, less common molds and dimorphic fungi. 39th Llterscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) p. 569, Abstract J–1509.
   Google Scholar
• CHIOU CC, MAVROGIORGOS N, WALSH TJ: Synergistic antifungal activity of nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 940.
   Google Scholar
• GROLL AH, MICKIENE D, PETRAITIENE R et al: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. (2001) 45:2845–2855.
   PubMed Web of Science ®Google Scholar
• LUCAS R, DESANTE K, HATCHER B et al.: LY303366 Single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA (1996).
   Google Scholar
• RAJMAN I, DESANTE K, HATCHER B et al.: LY303366 single intravenous dose pharmacokinetics and safety in health volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract F–74.
   Google Scholar
• NI L, SMITH B, HATCHER B et al.: Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract J–134.
   Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471–479.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. (1999) 43:2148–2155.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898–2905.
   PubMed Web of Science ®Google Scholar
• VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873–878.
   PubMed Web of Science ®Google Scholar
• STONE JA, HOLLAND SD, JU WD et al: Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract C–51.
   Google Scholar
• ARATHOON EG, GOTUZZO E, NORIEGA LM et al.: Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46:451–457.
   PubMed Web of Science ®Google Scholar
• HIEMENZ J, RAAD I, BOOGAERTS M et al.: Efficacy of caspofungin as salvage therapy in invasive aspergillosis compared to standard therapy in historial cohort. Focus on Fungal Infections I I Washington, DC (2001) Abstract 21.
   Google Scholar
• •A clinical study that demonstrates the efficacy of caspofungin as salvage agent in treatment of aspergillosis.
   Google Scholar
• MAERTENS J, RAAD I, SABLE CA et al: Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1103.
   Google Scholar
• KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44:1850–1854.
   PubMed Web of Science ®Google Scholar
• POWLES MA, LIBERATOR P, ANDERSON J et al: Efficacy of MK-991 (L,743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis Antimicrob. Agents Chemother. (1998) 42:1985–1989.
   PubMed Web of Science ®Google Scholar
• AZUMA J, YAMAMOTO I, OGURA M et al.: Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (1998) Abstract F–146.
   Google Scholar
• PETTENGELL K, MYNHARDT J, KLUYTS T, SONI P: A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-posit \ ive patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) Abstract J-1421:567.
   Google Scholar
• HIEMENZ J, CAGNONI P, SIMPSON D, DEVINE S, CHAO N: Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem Cell Transplant. patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) Abstract J-1648:576.
   Google Scholar
• IKEDA F, WAKAI Y, MATSUMOTO S et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. (2000) 44:614–618.
   PubMed Web of Science ®Google Scholar
• MAESAKI S, HOSSAIN MA, MIYAZAKI Y et al: Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chemother. (2000) 44:1728–1730.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO S, WAKAI Y, NAKAI T et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother. (2000) 44:619–621.
   PubMed Web of Science ®Google Scholar
• KOHNO S, MAESAKI S, IWAKAWA J et al.: Synergistis effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1686.
   Google Scholar
• ITO M, NOZU R, KURAMOCHI T et al: Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother. (2000) 44:2259–2262.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A, ARATHOON EG, GOTUZZO E et al: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2001) 33:1529–1535.
   PubMed Web of Science ®Google Scholar
• SABLE CA, NGUYEN B-Y, CHODAKEWITZ JA et al.: Safety of caspofungin acetate in the treatment of fungal infections. Focus on Fungal Infections 11. Washington, DC (2001) Abstract 21.
   Google Scholar
• KEATING GM, JARVIS B: Caspofungin. Drugs (2001) 61:1121–1129.
   PubMed Web of Science ®Google Scholar
• SELSTED M, SZKLAREK D, GANZ T, LEHRER R: Activity of rabbit leukocyte peptides against Candida albicans. Infect. Immun. (1985) 49:202–206.
   PubMed Web of Science ®Google Scholar
• ALCOULOUMBRE MS, GHARINOUM MA, IBRAHIM AS, SELSTED ME, EDWARDS JE: Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1993) 37:2628–2632.
   PubMed Web of Science ®Google Scholar
• SEGAL GP, LEHRER RI, SELSTED ME: hi vitro effect of phagocyte cationic peptides on Coccidioides immitis..1. Infect. Dis. (1985) 151:890–894.
   Google Scholar
• LEVITZ SM, SELSTED ME, GANZ T, LEHRER RI, DIAMOND RD: In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. 1 Infect. Dis. (1986) 154:483–489.
   Google Scholar
• LEHRER RI, GANZ T, SZKLAREK D, SELSTED ME: Modulation of the in situ candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. .1 Clin. Investig. (1988) 81:1829–1835.
   PubMed Web of Science ®Google Scholar
• GANZ T, SELSTED ME, SZKLAREK D et al.: Natural peptide antibiotics of human neutrophils.j Clin. Invest. (1985) 76:1427–1435.
   Google Scholar
• LAWYER CS, PALS, WATEBE M et al.: Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. J. Antimicrob. Chemother. (1996) 37:599–604.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI K, TOMITA M, GIEHL TJ, ELLISON RT: Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Iinmun. (1993) 61:719–728.
   PubMed Web of Science ®Google Scholar
• ERNST EJ: Investigational antifungal agents. Pharmacotherapy (2001) 21:165S–174S.
   Google Scholar
• BECKER JM, COVERT NL, SHENBAGAMURTHI P, STEINFELD AS, NAIDER F: Polyoxin D inhibits growth of zoopathogenic fungi. Antimicrob. Agents Chemother. (1983) 23:926–929.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB S, ALTBOUM Z, SAVAGE D, SEGAL E: Adhesion of Candida albicans to epithelial cells: effect of polyoxin D. Mycopathology (1991) 115: 197–216.
   Google Scholar
• IWAMOTO T, FUJIIE A, TSURUMI Y, NANBATA K, SHIBUYA K: FR900403, a new antifungal produced by a Kernia spp. Aritibiot. (1990) 43:1183–1185.
   PubMed Web of Science ®Google Scholar
• ARONEX PHARMACEUTICALS: US00640707 (1991).
   Google Scholar
• PFIZER LTD: EP-00440372 (1991).
   Google Scholar
• SCHERING CORP.: WO09517407 (1995).
   Google Scholar
• EISAI CO. LTD: EP-00667346 (1995).
   Google Scholar
• ELI LILLY & CO.: EP-00561639 (1993).
   Google Scholar
• MERCK & CO. INC.: W009421677 (1994).
   Google Scholar
• FUJISAWA PHARMACEUTICAL CO. LTD: W009823637 (1998).
   Google Scholar